Results 181 to 190 of about 693,900 (279)

sGC stimulator BAY 41‐8543 improves survival and ventricular function in a rat model of doxorubicin‐induced cardiomyopathy with nephrotic syndrome

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Anthracyclines such as doxorubicin (DOXO) remain a cornerstone of cancer therapy but are associated with a high risk of cardiotoxicity and subsequent heart failure (HF). Impairment of NO/soluble guanylyl cyclase (sGC)/cGMP pathway has been reported in anthracycline‐induced cardiomyopathy.
Olga Gawrys, Petra Škaroupková, Soňa Kikerlová, Zdeňka Vaňourková, Martina Hüttl, Olga Lenčová, Kasin Yadunandam Anandam, Svenja Stomberg, Sönke Behrends, Barbara Szeiffová Bačová, Matúš Sykora, Lisa Dietz, Peter Sandner, Luděk Červenka, Martin Štěrba   +14 more
wiley   +1 more source

Progression-free survival outcomes of PARP inhibitors in ovarian cancer: an exploratory analysis of treatment heterogeneity based on organ vulnerability. [PDF]

Front Oncol
Zhou X, Xiong X, Yang Z, Cao Z, Ni Q.
europepmc   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

British Journal of Pharmacology, EarlyView.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

Multimodal imaging reveals a lysosomal drug reservoir that drives heterogeneous distribution of PARP inhibitors. [PDF]

Nat Commun
R Moncayo C, Restuadi R, Zhang G, Marks D, Ortega-Prieto P, Doherty E, Lambie N, Whilding C, Andrew I, Montoya A, Patel B, Tyson K, Pennycook BR, Pendergast L, Wu V, Takats Z, Matthews N, Young GR, Verma P, Shliaha P, Game L, Lenhard B, McNeish I, Fotopoulou C, Barr AR, Cunnea P, Hall Z, Fets L.   +27 more
europepmc   +1 more source

Expanding the horizons of PARP inhibitors [PDF]

Nature Reviews Cancer, 2010
openaire   +2 more sources

NRF2/xCT‐Mediated Antioxidant Adaptation Attenuates Apoptosis Induced by ASCT2 Inhibition in Prostate Cancer

Cancer Science, EarlyView.
ASCT2 inhibition induces ROS accumulation and activates NRF2‐dependent xCT upregulation in prostate cancer. This adaptive response partially supports residual cystine acquisition and glutathione synthesis, whereas combined ASCT2 and xCT inhibition disrupts redox compensation and predominantly promotes apoptotic cell death.
Jiaxing Wei, Yasutaka Yamada, Takaaki Tamura, Masahiro Sugiura, Xue Zhao, Meng Ni, Adilan Aierken, Tomokazu Sazuka, Yusuke Imamura, Shinichi Sakamoto   +9 more
wiley   +1 more source

PARP inhibitors induce a senescence phenotype in non-small cell lung carcinoma cell lines. [PDF]

FEBS Open Bio
Huart C, Van den Abbeel M, Schifflers C, Bouhjar K, Scarmelotto A, Khelfi A, Wera AC, Michiels C.   +7 more
europepmc   +1 more source

Genetic Evolution in BRCA1‐Associated Breast Cancer Reveals Early Driver Mutations Shaping Tumor Features and Prognosis

Cancer Science, EarlyView.
Multi‐region sequencing of 57 BRCA1‐associated breast cancers identified TP53 as the dominant initial driver, defining a triple‐negative subgroup with biallelic BRCA1 loss and elevated genomic instability. TP53 truncating mutations were enriched in BRCA1 carriers and linked to reduced HRD, EMT activation, and a trend toward worse survival.
Li Hu, Zhongwu Li, Qiting Wan, Xingyu Liao, Yaxin Zhang, Qian Liu, Xinyun Ding, Hua Meng, Yifan Wu, Jie Sun, Juan Zhang, Lu Yao, Ye Xu, Yuntao Xie   +13 more
wiley   +1 more source

Prognostic Nomogram for Ovarian Cancer Patients on First-Line Maintenance Therapy With PARP Inhibitors: A Retrospective Cohort Study. [PDF]

Cancer Med
Tan S, Yang S, Duan X, Zhang Y.
europepmc   +1 more source

Selective Depletion of Tumor‐Infiltrating CD4+CCR8+ Tregs by AZ084, a Novel CCR8 Antagonist

Cancer Science, EarlyView.
AZ084, a novel CCR8 antagonist, selectively targets tumor‐infiltrating CD4+CCR8+ Tregs, reduces their immunosuppressive function, and decreases IL‐10/TGF‐β production. ABSTRACT Regulatory T cells (Tregs) are key mediators of immunosuppression in ovarian cancer, yet strategies for selectively targeting tumor‐infiltrating Tregs remain limited.
Yepeng Mao, Ziqi Tao, Shuna Liu, Zhijie Liu, Yuelu Zhang, Lingfei Zhou, Lina Yan, Ting Wang, Wenwen Shang, Jianfang Lou, Xi Huang, Xin Fu, Fang Wang   +12 more
wiley   +1 more source